0 items USD 0.00Clindamycin Antibiotic Market: Opportunities and Challenges
Clindamycin is a topical antibiotic that effectively reduces the symptoms and appearance of infections. Clindamycin has both bacteriostatic and bactericidal qualities, meaning that it stops bacteria from multiplying and directly killing harmful cells. Clindamycin is used to treat various bacterial infections, including:
- Skin infections, such as cellulitis, folliculitis, and abscesses
- Respiratory infections, such as pneumonia and bronchitis
- Bone and joint infections, such as osteomyelitis
- Dental infections, such as periodontitis and abscesses
- Infections in the pelvic region, such as pelvic inflammatory disease
- Staphylococcal infections, including MRSA (methicillin-resistant Staphylococcus aureus)
Clindamycin may also be used in combination with other antibiotics to treat more severe infections or to prevent bacterial infections in individuals with weakened immune systems.
1 . Clindamycin Market Scenario
The global clindamycin market is expected to experience significant growth over the next few years, driven by the increasing prevalence of infections and the rising demand for effective antibiotic treatments. The market is also expected to benefit from introducing new formulations and the increasing adoption of generic clindamycin products.
New formulations of clindamycin are expected to drive the growth of the market. For instance, the availability of clindamycin in the form of injections, creams, and gels is expected to increase the adoption of the drug and drive the demand for clindamycin.
However, the growth of the clindamycin market is expected to be hindered by the increasing resistance of bacteria to antibiotics. The widespread use of antibiotics, including clindamycin, has led to the development of antibiotic-resistant bacteria, which can be challenging to treat. This is expected to limit the effectiveness of clindamycin and other antibiotics, which could hinder the market's growth.
Reports Suggested for clindamycin Marketers/Manufacturers/Investors
2 . Clindamycin Market Segments
Based on product type, the global clindamycin market can be segmented into:
1. Clindamycin phosphate
Clindamycin phosphate is a semisynthetic antibiotic derived from the bacterium Streptomyces lincolnensis. It is produced by first isolating the clindamycin molecule from the bacterium through fermentation. The isolated molecule is then treated with phosphoric acid to form the phosphate salt, which increases its water solubility and stability. The resulting solution is then filtered and purified to remove any impurities, resulting in the final product, clindamycin phosphate.
Clindamycin phosphate is available in capsule and injection form (150mg/ml, 300mg/50ml, 600mg/50ml, and 900mg/50ml)
2. Clindamycin hydrochloride
The production of clindamycin hydrochloride typically involves the following steps:
- Synthesis of clindamycin: The starting material for the synthesis of clindamycin is 7-chloro-7-deoxy-lincomycin, which is derived from the fermentation of Streptomyces lincolnensis. This compound is subjected to a series of chemical reactions to form clindamycin.
- Purification of clindamycin: The crude clindamycin produced in the previous step is purified using a variety of techniques, such as recrystallization, chromatography, and crystallization, to remove impurities and obtain a pure product.
- Conversion of clindamycin to clindamycin hydrochloride: Clindamycin is converted to its hydrochloride salt by reacting it with hydrochloric acid. This reaction produces clindamycin hydrochloride, which is more stable and easier to handle than clindamycin.
- Formulation of clindamycin hydrochloride: The clindamycin hydrochloride obtained in the previous step is formulated into various forms, such as capsules, tablets, or injectable solutions, according to the intended use.
- Quality control and testing: The final product is subjected to various quality control tests to ensure its purity, potency, and stability. These tests may include physical and chemical tests, as well as microbiological and stability studies.
- Packaging and distribution: The finished product is packaged into appropriate containers and distributed to healthcare providers for the treatment of bacterial infections.
Reports Suggested for clindamycin Chemical/Salt/API Manufacturers
3 . Leading Clindamycin Market Players and Products
Major market players in the clindamycin industry are: Pfizer, Akorn, Almaject, Baxter, Sagent, Sandoz, Fresenius Kabi, Alvogen etc.
The list of the popular brands is as follows:
- Cleocin (clindamycin) is an antibiotic medication used to treat various bacterial infections, such as pneumonia, acne, and infections of the skin, bone, and female reproductive organs. It is manufactured by Pfizer.
- XACIATO™ : Daré Bioscience’s first FDA-approved product, XACIATO™ (clindamycin phosphate vaginal gel, 2%), is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. In March 2022, the company entered into an exclusive global license agreement with Organon to commercialize XACIATO. XACIATO is expected to be available commercially in the United States in the fourth quarter of 2022. With the closing, Daré will receive a USD 10 million upfront payment from Organon. Daré is eligible to receive potential milestone payments of up to USD 182.5 million and tiered double-digit royalties based on net sales.
- CLINDAGEL (clindamycin phosphate) gel, 1% is indicated for topical application in treating acne. In view of the potential for diarrhea, bloody diarrhea, and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. The brand is owned by Bausch Health Companies Inc, a Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada.
- Clinda-T (clindamycin phosphate) is a brand of antibiotic medication owned by Pharmacia and Upjohn Company LLC used to treat a variety of bacterial infections. It is a combination of clindamycin and tretinoin, which work together to kill bacteria and reduce inflammation in the affected area. Clinda-T is typically prescribed for skin infections, such as acne and folliculitis, but may also be used to treat other bacterial infections.
- Clindet (clindamycin phosphate) is a brand of a topical antibiotic that contains clindamycin, a medication used to treat bacterial infections of the skin. It is available in both gel and foam form.
- Clindamycin (as phosphate) 1%; pledgets; contains isopropyl alcohol 52%. Clindet owned by Stiefel Laboratories is an American dermatological pharmaceutical company. In 2009. Stiefel was acquired by GlaxoSmithKline at a price of USD 2.9 billion.
Disclaimer: The products mentioned here are not intended to diagnose, treat, cure, or prevent any disease. The information provided on this blog is marketing material for the informational purposes of pharma manufacturers, investors, and chemical manufacturers and should not be considered medical advice. Always consult with a qualified healthcare professional before taking any medication or supplement.
Email a colleague
Printer version
Send by email
About The Author
